Immunotech Biopharm Ltd (HKG:6978)

Immunotech Biopharm Cash Flow Statement

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Net Income	-186.91	-334.82	-318.11	-354.22
Depreciation & Amortization	59.3	52.22	43.11	20.82
Other Amortization	1.58	1.18	14.46	0.19
Loss (Gain) From Sale of Assets	0.04	-0.2	0.64	0.09
Asset Writedown & Restructuring Costs	0.56	-	-	-1.3
Loss (Gain) From Sale of Investments	19.81	90.01	24.02	18.79
Stock-Based Compensation	-	-	4.29	48.95
Other Operating Activities	-41.84	15.67	5.59	-7.04
Change in Inventory	-0.62	2.29	3.65	-6.89
Change in Accounts Payable	-17.7	4.09	8.41	38.87
Change in Unearned Revenue	0.56	-0.71	3.29	-0.35
Change in Other Net Operating Assets	39.48	6.63	29.74	-12.56
Operating Cash Flow	-125.74	-163.63	-180.92	-254.65
Capital Expenditures	-27.26	-19.58	-68.15	-146.01
Sale of Property, Plant & Equipment	0.03	0.96	1.5	0.21
Sale (Purchase) of Intangibles	-0.81	-2.96	-7.55	-22.32
Sale (Purchase) of Real Estate	-	-	-20.87	-12.91
Investment in Securities	140.83	-100	78.06	-150.09
Other Investing Activities	28.31	4.99	40.39	2.91
Investing Cash Flow	141.1	-116.6	23.38	-328.21
Long-Term Debt Issued	-	300	1	-
Total Debt Issued	-	300	1	-
Long-Term Debt Repaid	-13.1	-17.56	-17.43	-7.32
Total Debt Repaid	-13.1	-17.56	-17.43	-7.32
Net Debt Issued (Repaid)	-13.1	282.44	-16.43	-7.32
Other Financing Activities	-7.49	-8.52	-19.63	-3.68
Financing Cash Flow	-20.59	273.92	-36.06	-11
Foreign Exchange Rate Adjustments	0.02	0.02	0.65	-0.13
Net Cash Flow	-5.2	-6.29	-192.95	-593.99
Free Cash Flow	-153	-183.21	-249.07	-400.67
Free Cash Flow Per Share	-0.30	-0.36	-0.48	-0.78
Cash Interest Paid	7.49	8.52	6.14	3.68
Cash Income Tax Paid	-0.04	-	-	-
Levered Free Cash Flow	-134.61	-120.8	-146.34	-201.44
Unlevered Free Cash Flow	-129.93	-115.47	-156	-199.15
Change in Working Capital	21.72	12.31	45.09	19.07

Source: S&P Global Market Intelligence. Standard template. Financial Sources.